About Us
Hobson Prior is a leading provider of permanent and interim recruitment services for the clinical, medical and regulatory functions of life science businesses across Europe.
Since our formation in 2002, we have established relationships with a broad portfolio of candidates globally, providing a truly international resource for life science businesses seeking to recruit experienced clinical, medical and regulatory professionals.
Our highly focused services are driven by a defined quality management process, combined with our consultants’ indepth industry knowledge, and underpinned by compliance to the strict ethical and legal regulations which govern our industry and those of our clients.
Functional Expertise
Our services are focused solely on the source and supply of mid to upper level clinical, medical and regulatory specialists involved in drug discovery, clinical development and postapproval processes within the European life sciences industry.
Our consultants all specialise in a specific discipline, and combine in-depth industry knowledge with an ethical and proactive sourcing approach to deliver the right solution for each assignment.
Our consultants functional expertise incorporates:
• Clinical Data Management
• Clinical Research
• Drug Safety & Pharmacovigilance
• Medical Affairs
• Medical Information
• QA, QC & Validation
• Regulatory Affairs
• Statistics & SAS
Vacancy Search
Latest News
Anthera listing confirms weak IPO market
The disappointing public outing for Anthera Pharmaceuticals this week, eventually listing on the Nasdaq at a 50% discount to its proposed price, was not an encouraging sign for those US companies with active IPO filings at the SEC who must now be reassessing their next financing steps.
The weakness of Anthera’s IPO – $54m raised was the lowest since Cumberland Pharmaceuticals cracked open the IPO window last August – mirrors the poor performance of Omeros since it went public in October. Anthera and Omeros are both developmental stage, high risk investment opportunities, similar to five of the six companies currently pursuing an IPO. The one mature company on the list, Prometheus Laboratories, with eight marketed products and annual profits since 2005, therefore appears the standout IPO candidate, but only if it clears up uncertainty over rights to its biggest selling product (see tables below).
Investors still risk averse
Anthera was the fifth US pharmaceutical company to go public since the broader stock market recovery in the second half of 2009.
As the table below shows, the initial optimism that IPOs would start to flow has dampened as the two most recent public offerings, Anthera and Ironwood Pharmaceuticals, have only squeezed onto the market at a significant discount to the proposed price. The average discount between the filed price and the actual list price is 20%, even after some companies had already cut back their price targets.
